The metal and lipid nanoparticle manufacturing market is estimated to be worth USD 2.1 billion in the current year and is likely to grow at a CAGR of 8.6% during the forecast period, till 2035.
Consequently, participants in the metal and lipid nanoparticle manufacturing market are actively seeking methods to enhance or supplement the physicochemical attributes and drug-like characteristics of pharmacological products. Among other options, the application of nanoparticles has attracted the interest of numerous pharmaceutical developers. During the COVID-19 pandemic, the newly developed vaccines designed were encapsulated in a layer of lipid nanoparticles helping transport the active components to the intended area of effect. Additionally, numerous drug developers are utilizing lipid / metal nanoparticles to re-engineer current product candidates to enhance their bioavailability / biocompatibility.
However, certain nanoparticles used in medical industry have manufacturing processes that are very intricate, costly, and filled with various challenges, including the requirement for specialized knowledge (particularly with lipid nanoparticles), insufficient facilities with the requisite infrastructure, and issues concerning storage and stability. Given the routine operational and technical difficulties, a growing number of pharmaceutical firms have shown a preference for outsourcing their nanoparticle manufacturing processes to specialized service providers.
METAL AND LIPID NANOPARTICLE MANUFACTURING MARKET: GROWTH AND TRENDS
In recent decades, the pharmaceutical sector has experienced considerable growth, as reflected in the steadily increasing pipeline of drug candidates that have been launched or are under development at various development stages. A recent study featured in the journal of Analytical and Pharmaceutical Research has stated that approximately 90% of candidates in the ongoing preclinical development pipeline and over 40% of marketed pharmaceutical drugs are associated with issues concerning solubility / permeability. Additionally, it was observed that a pharmacological product exhibited a 10% decrease in robustness each time it was combined with another product, resulting from drug incompatibility.Consequently, participants in the metal and lipid nanoparticle manufacturing market are actively seeking methods to enhance or supplement the physicochemical attributes and drug-like characteristics of pharmacological products. Among other options, the application of nanoparticles has attracted the interest of numerous pharmaceutical developers. During the COVID-19 pandemic, the newly developed vaccines designed were encapsulated in a layer of lipid nanoparticles helping transport the active components to the intended area of effect. Additionally, numerous drug developers are utilizing lipid / metal nanoparticles to re-engineer current product candidates to enhance their bioavailability / biocompatibility.
However, certain nanoparticles used in medical industry have manufacturing processes that are very intricate, costly, and filled with various challenges, including the requirement for specialized knowledge (particularly with lipid nanoparticles), insufficient facilities with the requisite infrastructure, and issues concerning storage and stability. Given the routine operational and technical difficulties, a growing number of pharmaceutical firms have shown a preference for outsourcing their nanoparticle manufacturing processes to specialized service providers.
METAL AND LIPID NANOPARTICLE MANUFACTURING MARKET: KEY INSIGHTS
The report delves into the current state of the metal and lipid nanoparticle manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:- At present, more than 50 companies across the globe claim to have the required capabilities to offer a range of services for the development and manufacturing of lipid / metal nanoparticles.
- Several CMOs have the necessary expertise to provide production services for different types of nanoparticles across varied scales of operations; such players cater to the needs of a number of end users.
- Most of the players offering contract services for nanoparticles to different end users are headquartered in North America and Europe; the US and Germany have emerged as the most prominent countries within these regions.
- In order to gain an edge in this competitive industry, nanoparticle contract manufacturers are continuously undertaking initiatives to upgrade their existing service offerings.
- The growing interest is also evident from the rise in partnership activity; a major proportion of the deals were signed by companies based in North America.
- Driven by the rising demand for drugs that can overcome the existing challenges associated with solubility, the nanoparticle contract manufacturing market is estimated to grow at an annualized rate of 8.6%, till 2035.
- The projected market opportunity is likely to be distributed across different scales of operations, company size and key geographical regions.
METAL AND LIPID NANOPARTICLE MANUFACTURING MARKET: KEY SEGMENTS
Large Players Dominate the Metal and Lipid Nanoparticle Manufacturing Market
In terms of company size, the market is segmented across very small, small, mid-sized, and larger players. Currently, the metal and lipid nanoparticle manufacturing market is likely to capture around 40% of the overall market share. Further, the market for mid-sized players is likely to grow at a higher CAGR of 9.78%, during the given time period.Metal Nanoparticles are Anticipated to Dominate the Metal and Lipid Nanoparticle Manufacturing Market
In terms of nanoparticle manufactured, the market is segmented across lipid and metal nanoparticles. Currently, the metal nanoparticle manufacturing market is likely to capture around 60% of the overall market share. Further, the market for lipid nanoparticles will grow at a higher CAGR of 8.98%, during the given time period.Commercial Scale is Anticipated to Capture a Higher Metal and Lipid Nanoparticle Manufacturing Market Share
In terms of scale of operation, the market is segmented across preclinical, clinical and commercial segments. Currently, the majority (60%) of the metal nanoparticle manufacturing market is captured by commercial segment. Further, the market for preclinical and clinical segments is likely to grow at a higher CAGR of 9.24%, each during the forecast period.Pharmaceutical Companies are Likely to Hold Majority of the Metal and Lipid Nanoparticle Manufacturing Market Share
In terms of end-user, the market is segmented across educational institutions, pharmaceutical companies, research institutes, and other end users. Currently, the majority (60%) of the metal nanoparticle manufacturing market is captured by pharmaceutical companies. Further, the market for research institutes is likely to grow at a higher CAGR of 10.27%, during the forecast period.North America is Anticipated to Hold the Majority of the Metal and Lipid Nanoparticle Manufacturing Market Share
In terms of region, the market is segmented across North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World. Currently, the majority (40%) of the metal nanoparticle manufacturing market is captured by pharmaceutical North America. Further, the market in Middle East and North Africa is likely to grow at a higher CAGR of 10.83%, during the forecast period.Example Players in the Metal and Lipid Nanoparticle Manufacturing Market
- Ardena
- CordenPharma
- Curia
- Evonik
- LSNE Contract Manufacturing
- Polymun
- TechNanoIndia
METAL AND LIPID NANOPARTICLE MANUFACTURING MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the metal and lipid nanoparticle manufacturing market, focusing on key market segments, including [A] type of service, [B] company size, [C] type of nanoparticles manufactured, [D] scale of operation, [E] type of end-user [F] geographical regions.
- Market Landscape: provides a detailed assessment of nanoparticle contract manufacturers based on several relevant parameters, such as [A] company size, [B] location of headquarters, [C] type of organization, [D] type of nanoparticle(s) manufactured, [E] location and number of manufacturing facilities, [F] scale of operation, [G] type of end user, [H] type of service(s) offered, [I] quality certifications and [J] regulatory organizations.
- Company Competitiveness Analysis: A comprehensive competitive analysis of nanoparticle contract manufacturers, examining factors, such as [A] service strength and [B] partnership strength.
- Company Profiles: In-depth profiles of prominent players engaged in this domain that offer contract manufacturing services for nanoparticle(s), focusing on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
- Partnerships and Collaborations An insightful analysis of the partnerships and collaborations inked between stakeholders engaged in the metal and lipid nanoparticle manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
- Outsourcing: Go / No-Go Framework: An insightful analysis that highlights the various factors that need to be taken into consideration by nanoparticle-based therapeutics developers, while deciding whether to manufacture their respective therapeutics in-house or engage the services of a CMOs.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What is the current global capacity of developers?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with the Research Team
- Free Updated report if the report is 6-12 months old or older
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE
5. KEY INSIGHTS
6. COMPANY COMPETITIVENESS ANALYSIS
7. COMPANY PROFILES
8. PARTNERSHIPS AND COLLABORATIONS
9. OUTSOURCING: GO / NO-GO FRAMEWORK
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
LIST OF FIGURES
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ajinomoto Bio-Pharma Services
- Alfa Aesar
- Amplicon Biotech
- Applied Chemical Works
- Arcturus Therapeutics
- Ardena
- Ascendia Pharmaceuticals
- AstraZeneca
- AVANSA Technology & Services
- Avanti Polar Lipids
- Axolabs
- BASF
- BBI Group
- BioNTech
- BIOZOL Diagnostica
- BOC Sciences
- Caisson Biotech
- Cal Nano
- Cambridge Nanomaterials Technology
- CanSinoBIO
- Cayman Chemical
- CONTRACTOR BUSINESS CENTER
- Celonic
- Center for Applied Nanotechnology
- Cerion
- ChemConnection
- CliniSciences
- CordenPharma
- Creative Biolabs
- Croda
- Crystallics
- CureVac
- Curia
- CYBERNANO
- Cytodiagnostics
- Daiichi Sankyo
- Danaher
- DCN Dx
- Deakin University
- Dolomite Microfluidics
- E.M. Sullivan Associates
- Eikonix
- EMJapan
- Encapsula NanoSciences
- Entos
- European Commission
- Evonik
- Exelead
- Fortis Life Sciences
- FUJIFILM Holdings
- GHO Capital
- Howei Pharm
- Hongwu International Group
- i-DNA Biotechnology
- Idifarma
- Integrity Bio
- Larodan
- LEON
- LIPOSOMA
- LSNE Contract Manufacturing
- Meliorum Technologies
- Molchem Technologies UK
- MyBiotech
- Nagase Medicals
- Nanochemazone
- nanoComposix
- Nanocs
- NanoHybrids
- NanoMaterials Technology
- Nanomics Technologies
- Nanophase Technologies
- Nanoshel
- Nanostructured & Amorphous Materials
- NARD Institute
- NNCrystal
- Novo Holdings
- Nucleus Medical Media
- NVIGEN
- NYACOL® Nano Technologies
- Ocean NanoTech
- Osaka University
- Permira
- Pfizer
- Pharmavize
- Phosphorex
- Polymun
- Precision NanoSystems
- Pró-Análise
- Prodotti Gianni
- Santhiram Chemicals
- Seashell Technology
- Shionogi
- Sirnaomics
- SkySpring Nanomaterials
- Stanipharm
- Stratech Scientific
- Strem
- Syntagon
- T&T Scientific
- TechNanoIndia
- The Energy and Resources Institute (TERI)
- U.S. Army
- Vaxinano
- Veritas Technologies
- ZoneOne Pharma
Methodology
LOADING...
